Andy Lim

Emergency physician | @SCSMonash @Monash_FMNHS | #Stroke #Emergency

[Andy Lim @ALim0211]

At the cutting edge of stroke research right here in France #ESOC2022!
Here are nine things I learnt from nine trials today!
#NeuroTwitter

[Andy Lim @ALim0211]

¡Hola!

Looking forward to learning about the latest advances in stroke research.

See you soon in Barcelona!

#WSC2025

[EMA Journal @EMAJournal]

#OpenAccess
https://t.co/oTjsTQqAei

[Andy Lim @ALim0211]

Emergency department presentations appear to be increasing in acuity in the state of Victoria, Australia. This rising urgency should prompt the health system to anticipate and prepare accordingly.

@EMAJournal @VicGovDH
https://t.co/hn16JRB9Si

[Andy Lim @ALim0211]

Victorian roads are becoming deadlier despite an overall reduction in road injury burden.
https://t.co/SzKXqL1lX6

[EMA Journal @EMAJournal]

The contribution of clinical assistants to ED flow and length of stay

#OpenAccess

https://t.co/a93jQVijkb

@ALim0211 @WileyHealth @acemonline

[Andy Lim @ALim0211]

I've run the simulations and I believe we've discovered something interesting.

Aspirin and #ticagrelor appears to be superior to aspirin and #clopidogrel for minor #stroke when clopidogrel resistance has not been excluded.

https://t.co/DC31iTrLN5

@ClayJohnstonMD @GNtem1

[Andy Lim @ALim0211]

@FrontNeurol Thank you, @FrontNeurol, for sharing 🙏!

@SCSMonash @MonashUni @MonashHealth

[Andy Lim @ALim0211]

@VivliCenter @MonashUni Thank you for sharing 🙏!

@SCSMonash @MonashUni @MonashHealth

[Andy Lim @ALim0211]

@EMAJournal @WileyHealth @acemonline Thank you for sharing 🙏!

@SCSMonash @MonashUni @MonashHealth

[Andy Lim @ALim0211]

@ZHeart11768530 Thank you, @ZHeart11768530, for sharing 🙏!

@SCSMonash @MonashUni @MonashHealth @GNtem1

[Andy Lim @ALim0211]

@ZHeart11768530 Thank you, @ZHeart11768530, for sharing 🙏!

@SCSMonash @MonashUni @MonashHealth @GNtem1

[Andy Lim @ALim0211]

@AshuPJadhav Thank you, @AshuPJadhav, for sharing 🙏!

@SCSMonash @MonashUni @MonashHealth @GNtem1

[The Heart @ZHeart11768530]

🔴 Comparison of Dual Antiplatelet Therapies for Minor, Nondisabling, Acute Ischemic Stroke:

https://t.co/dd338VSWCV
#medtwitter #foamed #cardiology #CardioEd #CardioTwitter #Cardiogen #CVD #medtwitter #internalmedicine #hospitalist #meded #Medtwitter #Review #MedEd

[The Heart @ZHeart11768530]

✅DAPT w/ aspirin & ticagrelor has higher probability of being the superior Rx among pts w/ minor stroke w/n presence of CYP2C19 loss-of-function alleles has not been excluded.

✅For pts with TIA, superiority of aspirin & ticagrelor vs aspirin & clopidogrel was not demonstrated

[AshuJadhav @AshuPJadhav]

Comparison of Dual Antiplatelet Therapies for Nondisabling Acute Ischemic Stroke https://t.co/VaUa3ff7Wz

[Andy Lim @ALim0211]

Prof Shelagh Coutts announcing the results of the TEMPO-2 trial: no benefit and possibly harm in non-disabling minor stroke patients with intracranial occlusion treated with intravenous tenecteplase. #ESOC2024

[Andy Lim @ALim0211]

@JAMANetworkOpen @GNtem1 Just announced in Basel, Switzerland! Thank you for listening to my talk! #ESOC2024

[Andy Lim @ALim0211]

Just announced in Basel, Switzerland! Thank you for listening to my talk! #ESOC2024

[JAMA Network Open @JAMANetworkOpen]

Bayesian analysis suggests that DAPT with aspirin + ticagrelor has higher probability of being the superior treatment among patients with minor stroke when presence of CYP2C19 loss-of-function alleles has not been excluded. https://t.co/DTssAsbebK @ALim0211 @GNtem1

[JAMA Network Open @JAMANetworkOpen]

Bayesian analysis suggests that DAPT with aspirin + ticagrelor has higher probability of being the superior treatment among patients with minor stroke when presence of CYP2C19 loss-of-function alleles has not been excluded. https://t.co/DTssAsbebK @ALim0211 @GNtem1

[Andy Lim @ALim0211]

Prof Xiong captivating the audience with TRACE III - tenecteplase reduced disability for Chinese patients with LVO 4.5-24h after onset with no safety concerns. #ESOC2024